Letters to the Editor

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia

Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;
New York-Presbyterian Columbia University Medical Center, New York, USA;
Memorial Sloan Kettering Cancer Center, New York, NY, USA;
Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, USA;
Dept. of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, USA;
Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, USA;
Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA;
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA;
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA;
Weill Cornell Medicine School of Medicine, Long Island City, NY, USA;
Div of Hematology and Oncology,Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA;
Div of Hematology and Oncology,Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA;
Aptitude Health, Atlanta, GA, USA;
Novant Health, Charlotte, NC, USA;
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ, USA;
Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA;
Memorial Sloan Kettering Cancer Center, New York, NY, USA;
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA;
Department of Medicine, Cancer Center, Tufts Medical Center, Boston, MA, USA;
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA;
Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC, USA;
Dept of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, USA;
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA, USA;
Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA;
Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;
Department of Haematology, Addenbrookes, Cambridge, UK;
Nottingham University Hospitals NHS Trust, Nottingham, UK
Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC, USA;
Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, USA;
Memorial Sloan Kettering Cancer Center, New York, NY, USA;
Haematologica Early view Feb 20, 2020 https://doi.org/10.3324/haematol.2019.241539